Natera outlined its work with pharmaceutical firms to use the Signatera assay, while Luminex was bullish about its growing molecular diagnostics business.
Natera said its liquid biopsy assay Signatera is well suited for the immuno-oncology field, particularly pharmaceutical companies developing personalized vaccines.
The molecular diagnostics company reported total revenues of $56.7 million in the quarter, and saw its testing volume grow 15 percent over Q3 2016.
Researchers at Aarhus will use Natera's liquid biopsy assay to monitor colorectal cancer patients after surgery and chemotherapy.
The company is collaborating with two UK institutes to assess whether its Signatera ctDNA technology can detect disease recurrence in women treated for breast cancer.
Several commercial NIPT providers in the US said they are planning to participate in the new program.
The company says Panorama is the only NIPT that can tell whether twins are identical or fraternal, which can impact the clinical management of a pregnancy.
Natera said that this research collaboration and others will help it clinically validate its circulating tumor DNA assay Signatera.
The Index gained 4 percent, outperforming the Dow and the Nasdaq, but underperformed the Nasdaq Biotechnology Index, which rose 5 percent.
Natera has entered the oncology space with a ctDNA assay and sees its blood banking service as a way to eventually tap into the consumer genomics space.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.